N. Peled, J. Mazieres, D.M. Kowalski, W-S. Lam, M. Hochmair, M. Majem, S.H. Kim, A. C. Blanco, K. Cuppens, I.A. Casarini, O. Bylicki, B. Shim, J.B. Sørensen, M. Gilli, S.H. How, C. Schumann, C. Gonzalez Arenas, T. He, A. Samkari, S. Novello
{"title":"121P MK-7684A(vibostolimab [vibo] 加 pembrolizumab [pembro] 复方制剂)联合/不联合多西他赛治疗铂化疗(化疗)和免疫疗法后的转移性 NSCLC","authors":"N. Peled, J. Mazieres, D.M. Kowalski, W-S. Lam, M. Hochmair, M. Majem, S.H. Kim, A. C. Blanco, K. Cuppens, I.A. Casarini, O. Bylicki, B. Shim, J.B. Sørensen, M. Gilli, S.H. How, C. Schumann, C. Gonzalez Arenas, T. He, A. Samkari, S. Novello","doi":"10.1016/j.iotech.2023.100593","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":"37 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy\",\"authors\":\"N. Peled, J. Mazieres, D.M. Kowalski, W-S. Lam, M. Hochmair, M. Majem, S.H. Kim, A. C. Blanco, K. Cuppens, I.A. Casarini, O. Bylicki, B. Shim, J.B. Sørensen, M. Gilli, S.H. How, C. Schumann, C. Gonzalez Arenas, T. He, A. Samkari, S. Novello\",\"doi\":\"10.1016/j.iotech.2023.100593\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":192507,\"journal\":{\"name\":\"Immuno-Oncology and Technology\",\"volume\":\"37 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-Oncology and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.iotech.2023.100593\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy